Reimagining Medicine
Company overview
Financial review
2023 priorities
Appendix
KesimptaⓇ shows strong growth driven by a compelling product
profile
GROWTH
Sales evolution
USD m, % cc
Ex-US
US
66
50
99
289
239
195
147
109
Global sales +28% (cc) vs. Q3, driven by US¹
TRX +116% vs. PY (market +1%) 1,2
369
Q1
Q2
2021
Q3
Q4
Q1
Q2
Q3
Q4
2022
NBRX +43% vs. PY (market -8%) 1,2
B-cell NBRx share about 50% of MS market1,2
KesimptaⓇ B-cell NBRx share ~30% 1,2
Adding ~80-90 new writers/month 1,3
Fast initiation: <6 days for 80% patients 1,4
FY sales USD 1.1bn (+200% cc)
Confident in future growth
Powerful efficacy: 9/10 patients with NEDA-3 at year 45
Kesimpta
Convenience: 1 minute a month dosing from home or anywhere
NEDA - No Evidence of Disease Activity 1. Refers to US unless otherwise stated. 2. December 2022, IQVIA NPA (KesimptaⓇ) and IQVIA NPA adjusted by NSP (all others).
3. Data on file. 4. Measured as days between prescription and dispense of first dose. Refers to patients in KesimptaⓇ Patient Support Program. Data on file. 5. Kuhle, et al. Poster
6. The initial dosing period consists of 20 mg subcutaneous doses at Weeks 0, 1 and 2, thereafter once a month. Patient must take pen out of the refrigerator 15-30 minutes before self-
TRX total prescriptions. NBRxX new to brand prescription.
B-cell therapies as portion of MS market in NBRx.
presented at ECTRIMS, 26-28 October, 2022.
administering.
26 Investor Relations | Q4 2022 Results
✓ NOVARTIS | Reimagining MedicineView entire presentation